FFAI Jumps 50%, SPIR EPS Estimate Soars 37pp in Revision-Driven Rally
Five stocks surged after upward EPS estimate revisions, with FFAI leading at 50.0% and SPIR showing the largest single-revision magnitude at 36.7 percentage points. Analyst forward EPS growth revisions ranging from 12.9pp to 36.7pp triggered buying across micro-cap and small-cap names in consumer cyclical, healthcare, basic materials, and industrial sectors.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| FFAI | Consumer Cyclical | 2026-04-06 | +12.9pp | +50.0% |
| SLNO | Healthcare | 2026-04-05 | +9.5pp | +33.0% |
| LAC | Basic Materials | 2026-04-03 | N/A | +29.9% |
| CGEN | Healthcare | 2026-04-03 | N/A | +29.2% |
| SPIR | Industrials | 2026-04-05 | +36.7pp | +28.7% |
Why did FFAI stock jump in April 2026?
FFAI surged 50.0% (from $0.22 to $0.33) after analysts raised its forward EPS growth estimate from 50.3% to 63.2% on April 6.
The 12.9 percentage point upward revision reflected improving sentiment toward the EV manufacturer's near-term profitability outlook. No recent news catalyst was available, suggesting speculative trading amplified the earnings estimate response in this ultra-micro-cap consumer cyclical name. The stock has gained $0.11 per share since detection.
View screener snapshot from 2026-04-06 →
FAQ: FFAI
Why did FFAI stock jump 50% in April 2026?
FFAI jumped 50.0% from $0.22 to $0.33 after analysts raised its forward EPS growth estimate from 50.3% to 63.2% on April 6, a 12.9 percentage point revision.
Is FFAI a buy after the 50% rally?
The rally was driven by a 12.9pp EPS estimate revision, but FFAI trades at $0.33 as an ultra-micro-cap with thin volume and high volatility—caution is warranted.
What is FFAI's current EPS growth estimate?
FFAI's forward EPS growth estimate was revised upward from 50.3% to 63.2% as of April 6, 2026.
Why did SLNO stock jump in April 2026?
SLNO rallied 33.0% (from $39.49 to $52.51) after analysts raised its forward EPS growth estimate from 59.2% to 68.7% on April 5.
The 9.5 percentage point upward revision signals improving expectations for the specialty pharma company's near-term earnings trajectory. No recent news was available to explain the move, suggesting the EPS revision itself drove market re-pricing. The stock has gained $13.02 per share since detection.
View screener snapshot from 2026-04-05 →
FAQ: SLNO
Why did SLNO stock surge in April 2026?
SLNO surged 33.0% from $39.49 to $52.51 after analysts raised its forward EPS growth estimate from 59.2% to 68.7% on April 5, a 9.5 percentage point revision.
Is SLNO a buy after the 33% rally?
SLNO has gained 33.0% since its EPS revision on April 5, with the forward growth estimate now at 68.7%—momentum traders may find entry points limited at current levels.
What caused SLNO's surge?
Analysts raised SLNO's forward EPS growth estimate by 9.5 percentage points (from 59.2% to 68.7%) on April 5, triggering a 33.0% price rally with no news catalyst driving the move.
Why did LAC stock jump in April 2026?
LAC climbed 29.9% (from $4.04 to $5.25) as analysts maintained a 56.0% forward EPS growth estimate after detecting the move on April 3.
The sharp price appreciation reflects improving commodity sentiment toward lithium producers amid EV supply chain demand expectations. Small-cap materials stocks with strong growth estimates often attract speculative buying when macro tailwinds align. The stock has gained $1.21 per share over one week.
View screener snapshot from 2026-04-03 →
FAQ: LAC
Why did LAC stock jump 29.9% recently?
LAC climbed 29.9% from $4.04 to $5.25 after the screener detected it on April 3 with a 56.0% forward EPS growth estimate, supported by lithium commodity sentiment.
What is LAC's EPS growth projection?
LAC maintains a 56.0% forward EPS growth estimate, with the stock rallying 29.9% to $5.25 since April 3 detection.
Is LAC a buy after the 30% rally?
LAC has gained 29.9% with a 56.0% EPS growth estimate, riding lithium and EV sector momentum—commodity price sensitivity remains a key risk factor.
Why did CGEN stock jump in April 2026?
CGEN spiked 29.2% (from $2.26 to $2.92) as analysts maintained a 43.7% forward EPS growth estimate after detecting the move on April 3.
Healthcare and biotech stocks are particularly sensitive to earnings estimate revisions and pipeline catalysts, amplifying the price response in this small-cap Israeli biotech. The stock has gained $0.66 per share over one week, benefiting from sector-wide re-rating in speculative healthcare names.
View screener snapshot from 2026-04-03 →
FAQ: CGEN
What caused CGEN's surge in April 2026?
CGEN spiked 29.2% from $2.26 to $2.92 after the screener detected it on April 3 with a 43.7% forward EPS growth estimate, supported by healthcare sector momentum.
What is CGEN's current EPS growth estimate?
CGEN carries a 43.7% forward EPS growth estimate as of the April 3 detection, with the stock gaining 29.2% to $2.92 since then.
Is CGEN a buy after the 29% rally?
CGEN has risen 29.2% in one week with a 43.7% forward EPS growth estimate in the healthcare sector, though small-cap biotech volatility warrants careful position sizing.
Why did SPIR stock jump in April 2026?
SPIR jumped 28.7% (from $15.91 to $20.48) after analysts sharply raised its forward EPS growth estimate from 58.9% to 95.6% on April 5.
The 36.7 percentage point upward revision—the largest among today's movers—signaled a dramatic improvement in expected profitability, triggering aggressive buying in this small-cap industrial and space-infrastructure name. Investor interest in orbital data and satellite services has amplified the response to the earnings estimate change. The stock has gained $4.57 per share since detection.
View screener snapshot from 2026-04-05 →
FAQ: SPIR
Why did SPIR stock surge 28.7% in April 2026?
SPIR jumped 28.7% from $15.91 to $20.48 after analysts raised its forward EPS growth estimate from 58.9% to 95.6% on April 5, a 36.7 percentage point revision.
What caused SPIR's EPS estimate to soar?
SPIR's forward EPS growth estimate was raised by 36.7 percentage points to 95.6% on April 5—the largest revision among today's movers—triggering a 28.7% price rally.
Is SPIR a buy after the rally?
SPIR has rallied 28.7% with a 95.6% forward EPS growth estimate following a massive 36.7pp revision, though the elevated growth expectations increase risk of disappointment.
Today's EPS revision-driven movers span four sectors and five different stocks, indicating that analyst forward estimate adjustments remain a powerful price signal across micro-cap and small-cap names. The 12.9pp to 36.7pp revisions triggered price gains of 28.7% to 50.0%, confirming that earnings estimate momentum continues to drive market attention in speculative segments.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →